<DOC>
	<DOCNO>NCT00027924</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . Sometimes transplanted cell reject body 's normal tissue . Drugs cyclosporine may prevent happen . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow peripheral stem cell transplantation treat patient chronic myelogenous leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Chronic Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine incidence nonrelapse mortality 100 day allogeneic peripheral blood stem cell transplantation patient chronic myelogenous leukemia ( CML ) myelodysplastic syndrome ( MDS ) treat fludarabine busulfan . II . Determine incidence donor stem cell engraftment patient treat regimen . III . Determine incidence severity acute graft-vs-host disease patient treat regimen . IV . Determine incidence persistent recurrent CML MDS patient treat regimen . V. Determine safety regimen patient . OUTLINE : Patients receive condition regimen comprise fludarabine IV day -9 -6 oral busulfan every 6 hour day -5 -2 . Patients undergo allogeneic peripheral blood stem cell transplantation day 0 . Patients receive graft-vs-host disease prophylaxis comprise methotrexate IV day 1 , 3 , 6 , 11 cyclosporine orally IV twice daily day -1 100 followed taper day 180 . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) ( BCR/abl Philadelphia ( Ph ) chromosome positive ) Accelerated phase More 10 % le 30 % myeloblast promyelocytes marrow peripheral blood Perturbations white count , platelet count , hematocrit uncontrolled chemotherapy busulfan hydroxyurea Progressive splenomegaly refractory chemotherapy Extramedullary tumor Presence nonconstitutional cytogenetic abnormality addition single Ph chromosome , except Y Persistent unexplained fever bone pain Blast phase More 30 % myeloblast promyelocytes marrow peripheral blood Remission blast phase Less 10 % blast marrow peripheral blood history blast phase Any phase CML contraindication condition therapy cyclophosphamide OR Diagnosis myelodysplastic syndrome ( MDS ) follow subtypes : Refractory anemia ( RA ) RA ring sideroblast ( RARS ) Highrisk cytogenetics ( i.e. , monosomy 7 complex abnormality ) RA excess blast ( RAEB ) Presence 520 % blast marrow less 5 % blast peripheral blood RAEB transformation 2130 % blast marrow OR 5 % blast peripheral blood Chronic myelomonocytic leukemia Presence 20 % blast marrow , less 5 % blast peripheral blood , 1,000 monocytes/uL peripheral blood Secondary acute myeloid leukemia arise preexist MDS More 30 % blast marrow Any stage MDS contraindication condition therapy cyclophosphamide Related unrelated donor compatible HLAA , B , C , DRB1 , DQB1 antigens Mismatch single HLAA , B , C , DRB1 , DQB1 allele within broad serotype ( e.g. , A*0101 v 0102 ) crossover group ( e.g. , A*0101 v 0301 ) allow PATIENT CHARACTERISTICS : Age : 65 Performance status : Not specify Life expectancy : Not severely limited disease malignancy Hematopoietic : See Disease Characteristics Hepatic : No hepatic disease AST great 2 time normal Renal : Creatinine great 2 time normal OR Creatinine clearance least 50 % age , weight , height Cardiovascular : No cardiac insufficiency require treatment No symptomatic coronary artery disease Pulmonary : No severe hypoxemia ( pO2 less 70 mm Hg DLCO le 70 % predict ) No mild hypoxemia ( pO2 less 80 mm Hg DLCO le 60 % predict ) Other : HIV negative Not pregnant nurse PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent growth factor methotrexate administration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>